ThinkstockThe biotech meltdown that started in late February was an indiscriminate killer. The top mega-cap sector leaders were shot down in flames along with small cap names that have yet to make a dime.…
Allergan has been a great company, and it can still be one in the future. The question is whether this greatness will be as an independent company or as a subsidiary of Valeant Pharmaceuticals.
Dendreon is getting crushed, and the share price is down to levels not seen in a decade. The company's reported Provenge sales were again unimpressive. It feels like investor interest has died.
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
ThinkstockVIVUS Inc. (NASDAQ: VVUS) is going to have to explain how its diet pill Qsymia had lower prescription volumes sequentially. If you just look at the revenue number, it looks massively higher at $36.7…
Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower in the premarket.
Endocyte and Merck have terminated their joint late-stage study of an ovarian cancer treatment after the trials failed to show results. Endocyte expressed surprise at the recommendation to halt the trial.
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
thinkstockObamacare sign ups reached eight million, although the Obama administration put the figure higher because of 4.8 million sign ups for Medicaid and CHIP. The U.S. Department of Health and Human Services also disclosed that…
Teva Pharmaceutical is finding a bit of a sell-the-news reaction to its first-quarter earnings report. The company said revenues rose 2% from a year ago and net income rose by 8%.
Mylan reported first-quarter 2014 results before markets opened Thursday. The generic drug maker reaffirmed its full-year EPS guidance and hinted at an acquisition by the end of the year.
ThinkstockClean teeth are supposed to be good for heart health, and a way to avoid dentures and to avoid the drilling, which comes with cavities as well. Some people are more willing to go…
ThinkstockAvanir Pharmaceuticals, Inc. (NASDAQ: AVNR) is seeing a late day surge on Wednesday after news broke that the company has prevailed in a patent fight covering NUEDEXTA. This drug remains the only FDA-approved product…
ThinkstockThe intense analysis of quantitative managers may seem like drudgery, but it can turn up absolute gems for investors looking for solid long ideas. In fact, firms like RBC use as much as 18…
Merck & Co. reported mixed first-quarter 2014 results before markets opened Tuesday morning. The loss of market exclusivity continues to hurt the top line. Merck reaffirmed its forecast for the full year.